The effect of immune therapy on surgical site infection following Crohn's Disease resection

2013 ◽  
Vol 100 (8) ◽  
pp. 1089-1093 ◽  
Author(s):  
T. Serradori ◽  
A. Germain ◽  
M. L. Scherrer ◽  
C. Ayav ◽  
M. Perez ◽  
...  
2013 ◽  
Vol 56 (10) ◽  
pp. 1156-1165 ◽  
Author(s):  
Motoi Uchino ◽  
Hiroki Ikeuchi ◽  
Hiroki Matsuoka ◽  
Toshihiro Bando ◽  
Kaoru Ichiki ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Xingchen Cai ◽  
Weisong Shen ◽  
Zhen Guo ◽  
Yi Li ◽  
Lei Cao ◽  
...  

Background. Incisional surgical site infection (iSSI) is a frequent postoperative complication of abdominal surgeries in patients with Crohn’s disease (CD). In this study, we investigated the association between thickness of subcutaneous fat (TSF) and iSSI in patients with CD undergoing intestinal resections. Patients and Methods. Patients with CD who had undergone abdominal surgery from January 2014 to January 2017 were included in this retrospective study. Patients’ TSF and other possible predictors of iSSI, including clinical characteristics, preoperative medications, hematological index, surgery-related data, and postoperative outcomes, were collected. Univariate and multivariate statistical analyses were used to examine the potential factors. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of factors. Results. The patient cohort comprised 246 patients (167 male (67.9%); mean age 35.7 ± 12.4 years; mean disease duration 69.6 ± 60.8 months). The incidence of iSSI was 24.8% (61/246). TSF was a significant predictor of iSSI (OR 1.079, 95% CIs (1.020, 1.142), P=0.008), being 13.7 mm in patients with iSSI and 9.9 mm in those without iSSI (P<0.001). Additionally, C-reactive protein (CRP) concentrations (OR 1.059, P=0.003) were also possible predictors of iSSI, as indicated by both univariate and multivariate analysis. A model of iSSI comprising TSF and CRP concentrations was moderately accurate (AUC 0.827, CIs (0.766, 0.888)). Conclusions. Preoperative TSF and CRP independently affect iSSI in patients with CD undergoing intestinal resections.


2021 ◽  
Vol 14 (11) ◽  
pp. e245321
Author(s):  
Roghan Donohue Colbert ◽  
Daniel Gaya ◽  
Gordon Hale ◽  
William Rickaby

We present the rare case of a 61-year-old man with Crohn’s disease who developed a cutaneous Kaposi’s sarcoma in the setting of long-term treatment with 6-mercaptopurine. Deciding on the best course of management provided a clinical challenge in an ‘evidence-light’ area. Relevant case reports and guidelines were reviewed. In general, the withdrawal of immunosuppressive therapy is advised; however, a multidisciplinary, case-by-case approach is also emphasised. The patient’s lesion was removed and, following collaborative discussion, immunosuppression was continued post resection. This is thought to be the first reported case involving a Kaposi’s sarcoma in inflammatory bowel disease where immune therapy was not subsequently discontinued.


2001 ◽  
Vol 3 (Supplement 2) ◽  
pp. 58-62
Author(s):  
G. Olaison ◽  
P. Andersson ◽  
P. Myrelid ◽  
K. Smedh ◽  
J. Soderholm ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A68-A68
Author(s):  
G VANASSCHE ◽  
D VANBECKEVOORT ◽  
D BIELEN ◽  
G COREMANS ◽  
I AERDEN ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A3-A3
Author(s):  
C HASSAN ◽  
P CERRO ◽  
A ZULLO ◽  
C SPINA ◽  
S MORINI

Sign in / Sign up

Export Citation Format

Share Document